Parallel Advisors LLC raised its position in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 10.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 530 shares of the biotechnology company’s stock after purchasing an additional 50 shares during the period. Parallel Advisors LLC’s holdings in United Therapeutics were worth $119,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also bought and sold shares of the company. Baldwin Brothers LLC MA bought a new position in United Therapeutics during the fourth quarter valued at $38,000. Machina Capital S.A.S. bought a new position in shares of United Therapeutics in the first quarter worth $45,000. Neo Ivy Capital Management bought a new position in shares of United Therapeutics in the second quarter worth $48,000. Atlas Capital Advisors LLC bought a new position in shares of United Therapeutics in the fourth quarter worth $51,000. Finally, Northwestern Mutual Wealth Management Co. boosted its holdings in shares of United Therapeutics by 49.6% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 196 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 65 shares during the period. 95.02% of the stock is owned by institutional investors.
United Therapeutics Trading Up 1.6 %
NASDAQ UTHR opened at $237.91 on Wednesday. The stock’s 50-day simple moving average is $219.72 and its two-hundred day simple moving average is $233.93. United Therapeutics Co. has a twelve month low of $201.65 and a twelve month high of $283.09. The company has a quick ratio of 9.52, a current ratio of 9.84 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $11.15 billion, a price-to-earnings ratio of 16.02 and a beta of 0.61.
Wall Street Analyst Weigh In
A number of research firms have recently commented on UTHR. Morgan Stanley cut their price target on United Therapeutics from $320.00 to $316.00 and set an “overweight” rating for the company in a report on Monday, April 10th. Argus cut their price target on United Therapeutics from $300.00 to $280.00 and set a “buy” rating for the company in a report on Friday, April 21st. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 30th. UBS Group lowered their price objective on United Therapeutics from $330.00 to $310.00 and set a “buy” rating on the stock in a research report on Monday, April 10th. Finally, LADENBURG THALM/SH SH lowered their price objective on United Therapeutics from $285.00 to $256.00 in a research report on Thursday, May 4th. Two equities research analysts have rated the stock with a sell rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $294.67.
Insider Transactions at United Therapeutics
In other news, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction dated Thursday, April 20th. The stock was sold at an average price of $223.96, for a total value of $1,343,760.00. Following the transaction, the executive vice president now owns 36,599 shares in the company, valued at $8,196,712.04. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CEO Martine A. Rothblatt sold 8,000 shares of the firm’s stock in a transaction dated Friday, April 21st. The stock was sold at an average price of $228.82, for a total value of $1,830,560.00. Following the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $29,746.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction dated Thursday, April 20th. The stock was sold at an average price of $223.96, for a total value of $1,343,760.00. Following the completion of the sale, the executive vice president now directly owns 36,599 shares in the company, valued at $8,196,712.04. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 76,374 shares of company stock worth $17,072,439. Company insiders own 12.50% of the company’s stock.
United Therapeutics Profile
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Read More
- Five stocks we like better than United Therapeutics
- Green Hydrogen Stocks Getting Ready to Deliver Big Gains
- Charles Schwab Gets The Rebound, Time to Buy?
- Is Ebix Inc a Phygital E-Commerce Contender or Pretender?
- 3 Mid-Cap Stocks with Expectations for High-Earnings Growth
- Can Lockheed Martin Fly To A New High In 2023?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
